Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence 

Sanyal AJ, et al. Hepatol Comm. 2024

Serum ammonia levels do not correlate with overt hepatic encephalopathy severity in hospitalized patients with cirrhosis

Bajaj JS, et al. Clin Gastroenterol Hepatol. 2024

Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy

Ward JA, et al. World J Hepatol. 2023

Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)

Aspinall RJ, et al. Frontline Gastroenterol. 2023

Predicting hepatic encephalopathy in patients with cirrhosis: a UK population-based study and validation of risk scores

Jones BI, et al. Hepatol Commun. 2023

Integration of cirrhosis best practices into electronic medical record documentation associated with reduction in 30-day mortality following hospitalization

Sherman Z, et al. J Clin Gastroenterol. 2023

Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs

Jesudian AB, et al. J Med Econ. 2023

High rifaximin out-of-pocket costs are associated with decreased treatment retention among patients with hepatic encephalopathy

Aby ES, et al. Hepatol Commun. 2023

Role of oral health, frailty, and minimal hepatic encephalopathy in the risk of hospitalization: a prospective multi-center cohort of outpatients with cirrhosis

Bajaj JS, et al. Clin Gastroenterol Hepatol. 2023

Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium

Bajaj JS, et al. Lancet Gastroenterol Hepatol. 2023

Rifaximin use, adherence and persistence in patients with hepatic encephalopathy: a real-world study in the south of Italy

Pandico F, et al. J Clin Med. 2023

Add-on therapeutic effects of rifaximin on treatment-resistant hepatic encephalopathy

Hayakawa Y, et al. Intern Med. 2023

Lack of access to rifaximin upon hospital discharge is frequent and results in increased hospitalizations for hepatic encephalopathy

Stoll AM, et al. Ann Pharmacother. 2023

Hepatic encephalopathy-related hospitalizations in cirrhosis: transition of care and closing the revolving door 

Frenette CT, et al. Digestive Diseases and Sciences. 2022.

Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function 

Yokoyama K, et al. PLoS One. 2022.

Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α 

Deltenre P, et al. European Journal of Gastroenterology & Hepatology. 2021.

Overt hepatic encephalopathy: current pharmacologic treatments and improving clinical outcomes 

Rahimi RS, et al. The American Journal of Medicine. 2021.

Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands 

de Jong LA, et al. Journal of Medical Economics. 2021.

Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States 

Volk ML, et al. Journal of Medical Economics. 2021.

The role of the hospitalist in the continuum of care for patients with hepatic encephalopathy: treatment of inpatient episodes and preventing outpatient recurrence and readmissions 

Flamm SL, et al. Journal of Hospital Management and Health Policy. 2020.

Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy 

Jesudian AB, et al. Journal of Managed Care & Specialty Pharmacy. 2020.

A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy 

Vadhariya A, et al. Medicine. 2020.

Hepatic encephalopathy: more than just a change in mental status 

Williams JM, et al. Emergency Physicians Monthly. 2020.

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence 

Hudson M, et al. European Journal of Gastroenterology & Hepatology. 2019.

Understanding the impact of neurologic complications in patients with cirrhosis 

Allampati SK, et al. SAGE Open Medicine. 2019.

Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom 

Berni E, et al. Current Medical Research and Opinion. 2018.

Complications of cirrhosis in primary care: recognition and management of hepatic encephalopathy 

Flamm SL. The American Journal of the Medical Sciences. 2018.

Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin 

Neff G, et al. PharmacoEconomics. 2018.

A primary care guide to the diagnosis and management of overt hepatic encephalopathy 

Hameed B. Consultant. 2018.

The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS) 

Hudson M, et al. Frontline Gastroenterology. 2017.

Diagnosis of cirrhosis and evaluation of hepatic encephalopathy: common errors and their significance for the PCP 

Flamm SL. The Journal of Family Practice. 2017.

Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France 

Kabeshova A, et al. Therapeutic Advances in Gastroenterology. 2016.

Natural history of patients taking rifaximin-α for recurrent hepatic encephalopathy and risk of future overt episodes and mortality: a post-hoc analysis of clinical trials data 

Bannister CA, et al. Clinical Therapeutics. 2016.

How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist

Shawcross DL, et al. European Journal of Gastroenterology & Hepatology. 2016.

Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis 

Bajaj JS. Alimentary Pharmacology & Therapeutics [Supplement]. 2016.

The burden of rehospitalization for patients with liver cirrhosis 

Desai AP, et al. Hospital Practice. 2016.

Understanding the complexities of cirrhosis 

Muir AJ. Clinical Therapeutics. 2015.

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs 

Roggeri DP, et al. Hepatic Medicine. 2015.

Presentation and complications associated with cirrhosis of the liver 

Poordad FF. Current Medical Research and Opinion. 2015.

Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy 

Saab S. International Journal of General Medicine. 2015.

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis 

Bajaj JS, et al. Alimentary Pharmacology & Therapeutics. 2015.

Efficacy and tolerability of rifaximin in combination with lactulose in end-stage liver disease patients with MELD greater than 20: a single center experience 

Mantry PS, et al. Transplantation Proceedings. 2014.

Reply to: Rifaximin is largely safe and well-tolerated but caution is necessary when taken with statins 

Mullen KD. Clinical Gastroenterology and Hepatology. 2014.

Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy 

Mullen KD, et al. Clinical Gastroenterology and Hepatology. 2014.

Utility values for specific hepatic encephalopathy health states elicited from the general public in the United Kingdom 

Guest JF, et al. Health and Quality of Life Outcomes. 2014.

Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes 

Teperman LW. International Journal of Hepatology. 2013.

Update on management of patients with overt hepatic encephalopathy 

Chacko KR, et al. Hospital Practice. 2013.

Modulation of the fecal bile acid profile by gut microbiota in cirrhosis 

Kakiyama G, et al. Journal of Hepatology. 2013.

The intestinal microbiota and liver disease 

Bajaj JS, et al. The American Journal of Gastroenterology [Supplement]. 2012.

Lactulose: how many ways can one drug be prescribed?

Lukens B, et al. The American Journal of Gastroenterology. 2011.

Treatment of patients with hepatic encephalopathy: review of the latest data from EASL 2011 

Bass N. Journal of Gastroenterology and Hepatology [Supplement]. 2011.

Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy 

Bajaj JS, et al. Gastroenterology. 2011.

Rifaximin for the treatment of hepatic encephalopathy 

Mantry PS, et al. Transplantation Proceedings. 2010.

Rifaximin for the treatment of hepatic encephalopathy 

Mullen K, Prakash R. Expert Review of Gastroenterology & Hepatology. 2010.

The treatment of patients with hepatic encephalopathy: review of the latest data from EASL 2010 

Mullen KD. Journal of Gastroenterology and Hepatology. 2010.

Factors affecting compliance and persistence with treatment for hepatic encephalopathy 

Neff G. Pharmacotherapy [Supplement]. 2010.

Pharmacoeconomics of hepatic encephalopathy 

Neff G. Pharmacotherapy [Supplement]. 2010.

Clinical management of hepatic encephalopathy 

Schiano TD. Pharmacotherapy [Supplement]. 2010.

Treatment options for hepatic encephalopathy 

Schiano TD. Pharmacotherapy [Supplement]. 2010.

Introduction 

Thompson JR. Pharmacotherapy [Supplement]. 2010.

Treatment guidelines for hepatic encephalopathy 

Thompson JR. Pharmacotherapy [Supplement]. 2010.

The treatment of hepatic encephalopathy in the cirrhotic patient 

Sanyal AJ, et al. Journal of Gastroenterology and Hepatology. 2010.

Rifaximin treatment in hepatic encephalopathy 

Bass NM, et al. The New England Journal of Medicine. 2010.

Review article: The current pharmacological therapies for hepatic encephalopathy 

Bass NM. Alimentary Pharmacology & Therapeutics. 2007.

Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy 

Mullen KD. Alimentary Pharmacology & Therapeutics. 2007.

Review article: The burden of hepatic encephalopathy 

Poordad FF. Alimentary Pharmacology & Therapeutics. 2007.

Introduction: The burden, pathophysiology and management of hepatic encephalopathy 

Williams R. Alimentary Pharmacology & Therapeutics. 2007.

Review article: Bacterial flora and pathogenesis in hepatic encephalopathy 

Williams R. Alimentary Pharmacology & Therapeutics. 2007.